CA2449488C - Compositions and methods for treating hyperimmune response in the eye - Google Patents
Compositions and methods for treating hyperimmune response in the eye Download PDFInfo
- Publication number
- CA2449488C CA2449488C CA2449488A CA2449488A CA2449488C CA 2449488 C CA2449488 C CA 2449488C CA 2449488 A CA2449488 A CA 2449488A CA 2449488 A CA2449488 A CA 2449488A CA 2449488 C CA2449488 C CA 2449488C
- Authority
- CA
- Canada
- Prior art keywords
- antibodies
- eye
- antibody
- gamma
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title abstract description 39
- 230000000521 hyperimmunizing effect Effects 0.000 title abstract description 16
- 230000004044 response Effects 0.000 title description 8
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 19
- 102000008070 Interferon-gamma Human genes 0.000 claims abstract description 18
- 229960003130 interferon gamma Drugs 0.000 claims abstract description 16
- 239000012634 fragment Substances 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 18
- 206010052779 Transplant rejections Diseases 0.000 abstract description 8
- 208000030533 eye disease Diseases 0.000 abstract description 8
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 2
- 229940044627 gamma-interferon Drugs 0.000 abstract description 2
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 description 51
- 108010050904 Interferons Proteins 0.000 description 51
- 229940079322 interferon Drugs 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 25
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 21
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 230000001363 autoimmune Effects 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 210000004087 cornea Anatomy 0.000 description 7
- 239000006196 drop Substances 0.000 description 7
- 239000003889 eye drop Substances 0.000 description 7
- 229940012356 eye drops Drugs 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 230000005784 autoimmunity Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 206010013774 Dry eye Diseases 0.000 description 4
- 206010039705 Scleritis Diseases 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000006472 autoimmune response Effects 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 206010064996 Ulcerative keratitis Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 2
- 208000033379 Chorioretinopathy Diseases 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 2
- 206010015084 Episcleritis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
- 201000002287 Keratoconus Diseases 0.000 description 2
- 208000024599 Mooren ulcer Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010064997 Necrotising retinitis Diseases 0.000 description 2
- 208000007792 Orbital Pseudotumor Diseases 0.000 description 2
- 208000035452 Orbital pseudotumour Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000004709 chorioretinitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 201000004614 iritis Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 2
- 201000010668 orbital plasma cell granuloma Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002154 ionophoretic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29589501P | 2001-06-05 | 2001-06-05 | |
| US60/295,895 | 2001-06-05 | ||
| US09/894,287 | 2001-06-28 | ||
| US09/894,287 US6534059B2 (en) | 2001-06-05 | 2001-06-28 | Compositions and methods for treating hyperimmune response in the eye |
| PCT/US2002/017677 WO2002098460A1 (en) | 2001-06-05 | 2002-06-04 | Compositions and methods for treating hyperimmune response in the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2449488A1 CA2449488A1 (en) | 2002-12-12 |
| CA2449488C true CA2449488C (en) | 2010-02-09 |
Family
ID=26969391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2449488A Expired - Fee Related CA2449488C (en) | 2001-06-05 | 2002-06-04 | Compositions and methods for treating hyperimmune response in the eye |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6534059B2 (enExample) |
| EP (1) | EP1401496B1 (enExample) |
| JP (1) | JP2004532885A (enExample) |
| AT (1) | ATE343398T1 (enExample) |
| AU (1) | AU2002318175B2 (enExample) |
| CA (1) | CA2449488C (enExample) |
| DE (1) | DE60215649D1 (enExample) |
| WO (1) | WO2002098460A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6709655B2 (en) * | 2001-02-28 | 2004-03-23 | Instituto Bioclon, S.A. De C.V. | Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof |
| US6534059B2 (en) * | 2001-06-05 | 2003-03-18 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
| US6861056B2 (en) * | 2001-06-05 | 2005-03-01 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
| US6712976B2 (en) * | 2001-09-13 | 2004-03-30 | Abtech Industries, Inc. | Dual-action decontamination system |
| US7335759B2 (en) | 2002-12-02 | 2008-02-26 | Universidad Nacional Autónoma de Méxica (UNAM) | Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides |
| EP1651266B1 (en) * | 2003-07-25 | 2010-03-03 | Laboratorios Silanes, S.A. de C.V. | Administration of anti-tnf-alpha f(ab')2 antibody fragments |
| EA013118B1 (ru) | 2005-01-27 | 2010-02-26 | Новиммун С.А. | Антитела против интерферона-гамма и способы их применения |
| US20100003264A1 (en) * | 2005-03-24 | 2010-01-07 | Washington University | Reduction of Ophthalmalogic Neovascularization |
| US7381802B2 (en) * | 2005-04-15 | 2008-06-03 | Universidad Nacional Autónoma De México (UNAM) | Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom |
| WO2007145618A1 (en) * | 2006-06-12 | 2007-12-21 | Therakine Limited | Topical treatment for diseases of eye surface |
| US8697046B2 (en) | 2008-08-15 | 2014-04-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of administering interferon gamma to absorb fluid from the subretinal space |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| CA2985001A1 (en) | 2015-05-07 | 2016-11-10 | Novimmune Sa | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| HU206897B (en) | 1985-10-25 | 1993-01-28 | Zymogenetics Inc | Process for utilizing bar-1 gen for selecting strange proteins |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905400D0 (en) * | 1989-03-09 | 1989-04-19 | Jonker Margreet | Medicaments |
| DE69229275T2 (de) * | 1991-10-04 | 1999-12-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| DE19535073C1 (de) * | 1995-09-21 | 1997-02-20 | Roland Dr Grosmann | Verfahren zur künstlichen Inkubation von Hühnereiern |
| US6534059B2 (en) * | 2001-06-05 | 2003-03-18 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
| US6861056B2 (en) * | 2001-06-05 | 2005-03-01 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
-
2001
- 2001-06-28 US US09/894,287 patent/US6534059B2/en not_active Expired - Fee Related
-
2002
- 2002-06-04 CA CA2449488A patent/CA2449488C/en not_active Expired - Fee Related
- 2002-06-04 AT AT02747880T patent/ATE343398T1/de not_active IP Right Cessation
- 2002-06-04 AU AU2002318175A patent/AU2002318175B2/en not_active Ceased
- 2002-06-04 DE DE60215649T patent/DE60215649D1/de not_active Expired - Lifetime
- 2002-06-04 WO PCT/US2002/017677 patent/WO2002098460A1/en not_active Ceased
- 2002-06-04 JP JP2003501497A patent/JP2004532885A/ja active Pending
- 2002-06-04 EP EP02747880A patent/EP1401496B1/en not_active Expired - Lifetime
-
2003
- 2003-02-21 US US10/372,644 patent/US7232568B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004532885A (ja) | 2004-10-28 |
| EP1401496A4 (en) | 2005-08-31 |
| CA2449488A1 (en) | 2002-12-12 |
| US20020182212A1 (en) | 2002-12-05 |
| AU2002318175B2 (en) | 2006-01-05 |
| US20030224005A1 (en) | 2003-12-04 |
| ATE343398T1 (de) | 2006-11-15 |
| US6534059B2 (en) | 2003-03-18 |
| HK1063601A1 (en) | 2005-01-07 |
| US7232568B2 (en) | 2007-06-19 |
| EP1401496A1 (en) | 2004-03-31 |
| DE60215649D1 (de) | 2006-12-07 |
| WO2002098460A1 (en) | 2002-12-12 |
| EP1401496B1 (en) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2449488C (en) | Compositions and methods for treating hyperimmune response in the eye | |
| CA2637917C (en) | Therapeutic agents for diseases involving choroidal neovascularization | |
| WO2009014263A1 (ja) | インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤 | |
| AU2002318175A1 (en) | Compositions and methods for treating hyperimmune response in the eye | |
| EP1161954A1 (en) | Treatment of T cell mediated autoimmune disorders | |
| EP1004312A1 (en) | Method for treating multiple sclerosis | |
| CZ297083B6 (cs) | Cinidlo pro prevenci a lécbu zánetlivého onemocnení streva obsahující aktivní slozku antagonistu IL-6 | |
| US20040086508A1 (en) | Treatment of organ transplant rejection | |
| US6861056B2 (en) | Compositions and methods for treating hyperimmune response in the eye | |
| DE69736244T2 (de) | Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten | |
| HU211059B (en) | Method for producing pharmaceutical compositions usable for reducing immunglobulin e responses, containing human il-4 antibodies | |
| US20040062768A1 (en) | Compositions and methods for treating hyperimmune response in the eye | |
| JPH08506325A (ja) | サイトメガロウイルスに対するヒトモノクローナル抗体 | |
| US6333035B1 (en) | Medicinal composition containing gp34 binding-inhibitor as the active ingredient | |
| HK1063601B (en) | Compositions and methods for treating hyperimmune response in the eye | |
| US20050152902A1 (en) | Treatment of diabetic retinopathy | |
| US7462454B2 (en) | Treatment of herpes | |
| US20040247589A1 (en) | Anti-tumor activity from reptile serum | |
| JP2528549B2 (ja) | ヒトｉｌ―２レセプタ―重鎖に結合する新規モノクロ―ナル抗体 | |
| HK1062408B (en) | Remedies for infant chronic arthritis-relating diseases | |
| HK1062408A1 (zh) | 小儿慢性关节炎相关疾病治疗剂 | |
| HK1028554A (en) | Method for treating multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |